1 Comprehensive Evaluation of Clonal Hematopoiesis and Mosaic Loss of Y 2 Chromosome in Cardiovascular Risk: A Thorough Analysis in prospective studies 3 Fawaz S^{1*}, MD; Marti S^{2*}, PharmD; Dufossée M^{3*} MSc; Pucheu Y¹, MD; Gaufroy A¹, MD; 4 Broitman J¹,MD; Bidet A², PharmD, Soumaré A⁴ PhD, Munsch G⁴ PhD, Tzourio C⁴ MD PhD, 5 6 Debette S⁴ MD PhD, Trégouët DA⁴ PhD, James C^{2,3}, MD PhD; Mansier O^{2,3}, PharmD PhD; Couffinhal T^{1,3§} MD PhD 7 8 9 ¹ CHU de Bordeaux, Service des Maladies Coronaires et Vasculaires, F-33600 Pessac, 10 France 11 ² CHU de Bordeaux, Laboratoire d'Hématologie, F-33600 Pessac, France 12 Univ. Bordeaux, INSERM, Biologie des maladies cardiovasculaires, U1034, F-33600 13 Pessac, France ⁴ Univ. Bordeaux, Bordeaux Population Health Research Center, INSERM, UMR S 1219, F-14 15 33076, Bordeaux, France 16 * These authors contributed equally to this work 17 § These authors contributed equally to this work 18 19 Short title: CHIP do not highly increase the risk of MI even when associated with 20 **mLOY** 21 22 Corresponding authors 23 Pr Thierry Couffinhal. 24 thierry.couffinhal@inserm.fr 25 Dr Olivier Mansier. 26 olivier.mansier@inserm;fr 27 Inserm U1034 -1, avenue de Magellan, Hôpital Haut Lévêque - 33604 Pessac - France 28 Total word count: 4192

Abstract

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

Background: Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in Myocardial Infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this comprehensive study, we aimed to ascertain the precise risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP. Methods: We conducted a meticulous examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first myocardial infarction (MI) at the time of inclusion (MI(+) subjects), while 297 individuals from the 3-city cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP. **Results:** CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hsCRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in

55 MI(-) male subjects, CHIP heightened the risk of MI over a five-year period, particularly in 56 those lacking mLOY. 57 Conclusion: Our study highlights the high prevalence of CHIP and mLOY in elderly 58 individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation 59 substantially contribute to inflammation, atherosclerosis, or MI incidence. Furthermore, we 60 find that mLOY does not exert a significant influence on the modulation of inflammation, 61 atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may 62 accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings 63 underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, 64 suggesting that large-scale studies with thousands more patients may be necessary to 65 elucidate subtle correlations. 66 67 Keywords: Clonal hematopoiesis of indeterminate potential (CHIP); Mosaic loss of Y 68 chromosome; myocardial infarction; inflammation; atheromatous burden. 69 70 Author approval 71 All authors have seen and approved the manuscript. 72 Disclosures 73 The authors report no conflict of interest. 74 Sources of Funding 75 This study was supported by the Fondation Cœur & Recherche (the Société Française 76 de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » 77 consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of 78 Hematology of the University Hospital of Bordeaux benefitted of a convention with the 79 Nouvelle Aguitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq

Registration: URL: https://clinicaltrials.gov; Unique identifier: NCT04581057.

550Dx sequencer used in this study.

80

Introduction

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

Atherothrombosis is the main cause of death worldwide. Traditional cardiovascular risk factors (CVRF), such as diabetes, smoking, dyslipidemia, hypertension, explain 70 to 75% of cardiovascular events suffered by patients. However, a significant part of these events remains unexplained given that 25 to 30% of people without any evident cause can present an atherosclerotic cardiovascular event (CVE), whereas not all high-risk subjects (according to traditional CVFR) experience such an event.¹ Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a potential new risk factor of cardiovascular diseases.² This condition results from the acquisition by a hematopoietic stem cell of somatic mutations in leukemia-driver genes, leading to clonal expansion of a population of hematopoietic cells without any clinical or biological sign of hematological malignancy. The definition of CHIP proposed to date, requires the detection of the mutation at a variant allele frequency (VAF) of more than 2%, representing a proportion of mutated cells of more than 4%.3 The most commonly mutated genes in CHIP are DNA Methyltransferase 3A (DNMT3A) and Ten Eleven Translocation 2 (TET2). In 2014, Jaiswal et al showed that CHIP was associated with a decreased survival mainly because of an increased atherothrombotic mortality. In particular, they observed a 2.0 fold-increased risk of myocardial infarction (MI) and a 2.6-fold increased risk of ischemic stroke.² In 2017, these data were confirmed, showing a 1.9-fold increased risk of coronary heart disease in the presence of CHIP, independently of traditional CVRF.4 At the same time, a causative role of CHIP in inducing atherosclerosis has been demonstrated in animal models through the induction of a proinflammatory state. 4,5 More recently, Kessler et al showed in 454 803 subjects from the UK Biobank that the association of CHIP with atherothrombotic events was restricted to high VAF clones (ie ≥10%) with a much lower risk than initially demonstrated (HR=1.11).6 But even with these criteria, no association between CHIP and atherothrombotic events was found in a validation cohort of 173 585 subjects. which has also been suggested in another work studying several hundred thousand subjects. Thus, the impact of CHIP on atherothrombosis in humans is not totally evident, possibly because of the existence of yet

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

unidentified modulating factors that could potentiate or counteract the effect of CHIP. For example, the p.Asp358Ala variant of the IL6 receptor gene has been shown to decrease the atherothrombotic risk associated with CHIP. 8,9 However, the impact other genetic variants on the cardiovascular risk associated with CHIP remains unknown. Gain or loss of chromosomes in hematopoietic cells appears to be as frequent as the acquisition of somatic mutations during aging. 10 In particular, mosaic loss of chromosome Y (mLOY) has been shown to be frequent in male subjects without evidence of hematological malignancy. 11,12 mLOY was associated with cardiovascular diseases, 13,14 and can be detected in a rather high proportion of subjects with CHIP. 15,16 Finally, while TET2 mutations promote inflammation and atherosclerosis in mouse models.4 mLOY was shown to switch macrophages from a pro-inflammatory to a pro-fibrotic phenotype. 14 Thus, because of their opposite effect on macrophages phenotype, mLOY could balance the effect of CHIP regarding the induction of inflammation and thus decrease the development of atherosclerosis and the resulting atherothrombotic risk. We thus hypothesized that mLOY could modulate the effect of CHIP in inducing inflammation, atherosclerosis and triggering atherothrombotic events. In this study, we used sensitive technics to determine the prevalence of both CHIP and mLOY in 2 cohorts of subjects. We sought to determine whether CHIP and mLOY significantly increase the cardiovascular risk separately. We also searched to determine in humans whether mLOY could impact the effect of CHIP on inflammation, atherosclerosis burden or atherothrombotic risk.

Methods

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

Patients

For this study, we recruited 446 patients: 149 with a first MI and 297 without a MI or other CVE at inclusion. The 149 subjects with a MI were enrolled in the CHAth study between March 2019 and October 2021 (MI(+) subjects). The main eligibility criterion was suffering from a first MI of atherosclerosis origin after 75 years of age without evidence of hematological malignancy (Supplementary Figure S1). They were included between 4+/-2 months after the acute event, in order to assess their basal inflammatory state. In the presence of any clinical sign or factor associated with inflammation, the appointment was reported in order not to skew biological and genetic data. Additionally, we ensured that the subjects had not been vaccinated against SARS-Cov2 within 15 days of enrollment. The study was approved by the institutional review board (IRDCB 2019-A02902-05), and registered (https://www.clinicaltrials.gov: NCT04581057). All participants gave written informed consent before inclusion in the study. Eligibility and exclusion criteria are more detailed in the Supplementary Methods. As a control cohort, we selected subjects without any history of CVE at inclusion in the 3-city (3C) study cohort (MI(-) subjects, Supplementary Figure S1).¹⁷ The 3C study is a prospective study that enrolled 9294 subjects of 65 years or more who were selected upon electoral lists. These subjects were followed for several years (up to 12 years) to detect the development of dementia from a vascular origin. As such, they benefitted from a stringent cardiovascular follow-up, with adjudication of all cardiovascular events (in particular occurrence of MI). Among these subjects, we selected the 297 subjects who did not present any CVE before inclusion. Seventy-nine of them presented a MI during follow-up. The remaining 218 subjects had no atherothrombotic event during follow up, and were matched on age, sex and CVRF with those who had a MI during follow up (Supplementary Figure S1).

Clinical and biological parameters measured at inclusion

In MI(+) subjects, a routine cardiovascular evaluation was performed at inclusion (between 2 and 7 month after MI occurrence). Subjects were asked about presence of dyspnea or angina, evaluated with NYHA and CCS scales. Information was obtained from medical records about a potential recurrence of a cardiovascular event since the index event (new MI, coronary revascularization, stroke, hospitalization for acute heart failure). Traditional cardiovascular risk factors were noted. Routine biological analyses comprising blood count, high-sensitive CRP (hsCRP), lipid profile, HbA1c were performed in the laboratory of the university hospital of Bordeaux on fresh samples.

For MI(-) subjects, data available at inclusion included hsCRP level, lipid profile and traditional CVRF. No blood count was available but none of the subjects developed cancer (including hematological malignancy) during follow-up suggesting that detectable somatic mutations were indicative of CHIP and not hematological malignancy.

Measurement of atherosclerosis burden

For MI(+) subjects, a transthoracic echocardiography was performed at inclusion by trained cardiologists and ejection fraction calculated. Supra-aortic trunks ultrasonography with 3D-measurement of atherosclerotic volume was performed by trained physicians, using a Philips iU22 probe equipped with a linear-3D volume convertor VL13-5 (Philips). Images were analyzed using the Vascular Plaque Quantification software on the QLAB 10.2 system (Philips). Carotid stenosis quantification was done with NASCET criteria. Functional ischemic testing was performed at the clinicians' discretion. For MI(-) subjects, atherosclerosis burden was assessed at the inclusion by ultrasound echography recording detection of atherosclerotic plaques, atherosclerotic plaque numbers and intima-media thickness.

Follow up of subjects

For MI(+) subjects, the follow-up was conducted with a standardized questionnaire previously validated in clinical trials. Recurrence of MI as well as any significant cardiovascular event (cardiovascular death, acute coronary syndrome, stroke or transient

ischemic attack, congestive heart failure, secondary coronary revascularization, or peripheral vascular surgery) occurring between the initial event and the year after inclusion in the study were recorded. All medical records of participants who died, or who reported on the questionnaire that they had experienced cardiovascular symptoms between baseline and follow-up evaluations, were reviewed by one of the investigators, and the patient practitioners were contacted. For MI(-) subjects, a follow up was performed for up to 12 years. All cardiovascular events were recorded (including MI) with adjudication upon medical records by an expert committee (Figure 1).

Search for somatic mutations and mosaic loss of chromosome Y

For both MI(+) and MI(-) subjects, DNA was extracted from total leukocytes obtained at inclusion. The search for somatic mutations was carried out by the Laboratory of Hematology of the University Hospital of Bordeaux using the Next Generation Sequencing (NGS) panel designed for the diagnosis and follow-up of myeloid hematological malignancies. The genes tested are detailed in Supplementary Table S1.

Briefly, target sequences were captured using the SureSelect technology (Agilent). Sequencing was performed on a NextSeq 550Dx Instrument (Illumina technology) and analyzed using an in-house bioinformatics pipeline (see Supplementary Methods for more details). Variants interpretation was performed independently by two biologists according to criteria previously described and reported in Supplementary Table S2. According to the definition of CHIP, only mutations with a VAF \geq 2% were retained.

The search of mLOY was performed thanks to an in-house droplet digital PCR technic using the following primers and probes:

- Primer-amel-Fwd : 5'- CCCCTGGGCACTGTAAAGAAT
- 214 Primer-amel-Rev: 5'- CCAAGCATCAGAGCTTAAACTG
- 215 Probe-amelX: 5'- HEX-CCAAATAAAGTGGTTTCTCAAGT-BHQ

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

Probe-amelY: 5'- FAM-CTTGAGAAACATCTGGGATAAAG-BHQ. Briefly, 75 ng of DNA was mixed with ddPCR supermix for Probes (no dUTP, Biorad), primers (0.9µM each) and probes (0.25µM each). The emulsion was prepared with the QX-100 (Biorad). The amplification program was as follows: 10-minutes denaturation at 95°C. followed by 40 cycles of 30 seconds at 94°C, 1 minute at 55°C, and inactivation of 10 minutes at 98°C. The number of droplets positive for amelX and amelY was determined on the QX-200 droplet reader (Biorad) using the Quantasoft software version 1.5 (Biorad). At least 10,000 droplets were analyzed in each well. A cut off of 9% of cells with mLOY defined the detection of a mLOY based on the study of 30 men of less than 40 years who had a normal karyotype as assessed by conventional cytogenetic study. Statistical analyses Univariate association analyses were conducted using Fisher exact or Chi-square test statistics for categorical variables. Analysis of variance was used for quantitative variables. Multivariate association analyses were performed using logistic or linear regression models as appropriate. Analyses were adjusted for age and sex (CHIP) or for age only (mLOY). We used raw values for all quantitative variables as they presented a normal distribution, except for CRP levels for which we analyzed log(CRP). Log-rank test statistics were employed to assess the association of clinical/biological variables with the incidence of future cardiovascular events. All analyses were conducted using either the RStudio software (Posit team (2023). RStudio: Integrated Development Environment for R. Posit Software, PBC, Boston, MA. URL http://www.posit.co/.) or the PRISM software (GraphPad Prism version 9.5.1).

Results

Patient's characteristics

In this study, we aimed to decipher whether mLOY could alter the effect of CHIP in inducing a chronic inflammation that would favor the development of atherosclerosis and the incidence of atherothrombotic events. To answer this question, we analyzed 446 subjects from 2 prospective studies, 149 who presented a MI at inclusion and 297 who did not present any CVE before inclusion. The general characteristics of the 446 combined subjects are detailed in Table 1. Briefly, the median age was 76.4 years and 257 (57.6%) were males. Forty percent of them presented more than 2 CVRF. MI(+) subjects were older (due to the inclusion criteria), more frequently men, and presented a lower cardiovascular risk than MI(-) subjects (due to the initiation of treatment between the initial event and the inclusion).

CHIP and mLOY are detected as frequently in MI(+) and MI(-) subjects

Among the 446 subjects, at least one mutation with a VAF≥2% was detected in 201 persons (45.1%), defining CHIP(+) subjects (Table 1, Figure 1A). As previously described, *DNMT3A* and *TET2* were the 2 most frequently mutated genes. The other mutated genes were those previously described in CHIP (Figure 1B)^{2,4,16} and the median VAF was 2% (Figure 1C). The mutational profile of CHIP(+) subjects is available in the Supplementary Tables S3 and S4 while the characteristics of CHIP(+) compared with CHIP(-) subjects are detailed in the Supplementary Tables S5 and S6. In this study, we considered subjects without any detectable mutation or with only mutations with a VAF below 2% as non-CHIP carriers (CHIP(-) subjects).

A mLOY was present in 83 (37.7%) male subjects (mLOY(+) subjects, Table 1, Figure 1A). The clinico-biological characteristics of mLOY(+) subjects compared with mLOY(-) subjects are detailed in the Supplementary Tables S5 and S6. The median proportion of cells with mLOY was 18% [12%;32%]. There was no significant association between CHIP and mLOY since 39 CHIP(+) subjects (39.8%) also carried a mLOY compared with 44 CHIP(-) subjects (36.1%, p=0.579). Finally, as previously demonstrated, CHIP(+) subjects

were significantly older than CHIP(-) subjects (Supplementary Tables S5 and S6). We also observed an increasing prevalence of both CHIP and mLOY with age (Figure 1D).

We observed a similar frequency of CHIP and mLOY in MI(+) and MI(-) subjects (Figure 1A, Table 1). Besides, the association of CHIP with mLOY was as frequent in MI(+) and MI(-) subjects (22.7% and 13.8%, p=0.797). Of note, MI(+) and MI(-) subjects presented similar proportions of mutated genes (Figure 1B) and VAF (Supplementary Figure 2). Similar results were also observed when considering CHIP associated with important clones (*i.e.* VAF≥5%, Table 1). or when analyzing only *DNMT3A* and *TET2* mutations (data not shown).

Altogether, these results suggest that CHIP and mLOY are very frequent but not associated with the existence of a history of MI, even when mLOY is associated with CHIP.

Neither CHIP, mLOY, nor their combination highly increase basal inflammation or atherosclerotic burden

It was demonstrated that *TET2* mutations were associated with the induction of a proinflammatory phenotype of macrophages. On the contrary, mLOY was shown to decrease
the inflammatory phenotype of macrophages. Therefore, we searched to determine
whether mLOY could counter the inflammatory state that would be associated with CHIP. In
the total cohort, CHIP(+) and CHIP(-) subjects presented similar levels of hsCRP, as did
mLOY(+) and mLOY(-) subjects (Table 2). Similarly, hsCRP levels were not different in
CHIP(-)/mLOY(-), CHIP(+)/mLOY(-), CHIP(-)/mLOY(+) and CHIP(+)/mLOY(+) subjects. The
impact of CHIP and mLOY on hsCRP levels, either alone or in combination, was comparable
in MI(+) or MI(-) subjects (Table 2).—This was also true when restricting the analysis to

DNMT3A and TET2 mutated CHIP(+) subjects (Supplementary Table S7). Finally, subjects
with important CHIP or mLOY clones did not present higher levels of hsCRP (Supplementary
Table S8).

Very few data are available about atheroma burden associated with CHIP and/or mLOY in humans. Moreover, the modulation of the atherogenic effect of CHIP by mLOY remains unexplored. We thus asked whether CHIP alone or in association with mLOY was

associated with an increased atherosclerotic burden. In MI(+) subjects we observed a similar proportion of multitroncular coronary lesions and carotid stenosis >50% in CHIP(+) and CHIP(-) subjects (Table 3). The global atheroma volume was explored by 3D ultrasound in 34 MI(+) patients, without difference between CHIP(+) and CHIP(-) subjects. Similar results were obtained when analyzing only CHIP(+) subjects carrying *TET2* and/or *DNMT3A* mutations (Supplementary Table S7), when comparing mLOY(+) and mLOY(-) subjects (Table 3), or when analyzing the association of CHIP with mLOY (Supplementary Table S9). Concordantly, in MI(-) subjects, all available atherosclerosis markers were similar between CHIP(+) and CHIP(-), as well as between mLOY(+) and mLOY(-) subjects (Table 3). This was also true when analyzing the effect of the different combinations of CHIP and mLOY (Supplementary Table S9). Once again, all these results were confirmed in subjects with a VAF ≥5% for CHIP or a mLOY≥50% (Supplementary Table S8).

Altogether, our results suggest that both in the context of a recent MI and in healthy individuals, CHIP were not associated with a systemic inflammation or an increased atherosclerotic burden. mLOY do not modulate inflammatory parameters or atherosclerosis, even in the presence of CHIP.

Neither CHIP, mLOY, nor their combination highly impact the incidence of MI.

To decipher whether mLOY could impact the atherothrombotic risk associated with CHIP, we analyzed the incidence of MI during the follow-up of MI(-) subjects. Seventy-nine subjects developed a MI after inclusion in the study with a median delay of 5.00 years. Subjects with MI during follow-up did not differ significantly from those without MI in terms of demography or cardiovascular risk (Supplementary Table S10). CHIP, mLOY and their association were not significantly associated with an increased incidence of MI (Figure 2A-B, Supplementary Table S11). Concordantly, we did not observe any difference in the prevalence of CHIP, mLOY or their association between MI(-) subjects who suffered from a MI during follow up and those who did not (Supplementary Table S10). This was also the case when restricting the analysis to CHIP with a VAF ≥5%, a proportion of cells with mLOY

≥50% or to CHIP associated with *DNMT3A* or *TET2* mutations (Supplementary Figure S3A-S3B, Supplementary Table S10). These results suggest that the atherothrombotic risk associated with CHIP is moderate, and is not modulated by its association with mLOY. Moreover, neither CHIP, mLOY nor their combination were significantly associated with atherothrombotic recurrence (Supplementary Table S11).

CHIP in the absence of mLOY may accelerate the occurrence of MI

In order to search for a combined effect of CHIP with mLOY on the risk of incidence of MI, we finally focused our analysis on MI(-) male subjects. In this population, we observed that MI occurred earlier in CHIP(+) subjects, with a significant increased 5-year incidence of MI (log-rank test, p=0.0142, Figure 2C). Such an effect was not observed in MI(-) female subjects (log-rank test, p=0.9402, Supplementary Figure S3C). Interestingly, this effect was more pronounced in CHIP(+)/mLOY(-) subjects who presented a significantly higher 5-year incidence of MI (log-rank test, p=0.0104, Figure 2D) and a significantly lower median time to MI compared with other subjects (Kruskall-Wallis test, p=0.007). Altogether, our results suggest that CHIP do not increase the risk of MI, but may accelerate its incidence, particularly in the absence of mLOY.

Discussion

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

Clonal hematopoiesis of indeterminate potential (CHIP) has previously been implicated in decreased overall survival, primarily due to its association with an increased incidence of cardiovascular diseases such as coronary artery disease (CAD) and stroke.^{2,4} Experimental models have suggested that this association may arise from the pro-inflammatory phenotype of mutated monocytes/macrophages, contributing to the development of atherosclerotic plagues.^{4,5} However, recent findings in the literature have presented a complex and sometimes contradictory picture. Studies have reported varying results regarding the relationship between CHIP, inflammation markers, and atherothrombotic events, challenging the initial notion of a high atherothrombotic risk associated with CHIP. 6,7,9,20,21 Moreover, there has been a scarcity of evidence linking CHIP to an increased burden of atherosclerosis in human subjects. 4,22 Additionally, limited data are available on the potential impact of chromosomal abnormalities, particularly mosaic loss of the Y chromosome (mLOY), on atherothrombosis in individuals with CHIP. In this study, we sought to investigate whether mLOY could modulate the effects of CHIP concerning systemic inflammation, atherosclerotic burden, and the risk of atherothrombotic events. To achieve this, we employed sensitive techniques, including targeted high-throughput sequencing and digital PCR, to analyze samples from two cohorts of meticulously phenotyped subjects. In contrast to many previous studies, we conducted a comprehensive analysis involving two distinct cohorts. The "cases" were individuals recruited from the CHAth study within 2 to 7 months following their first myocardial infarction (MI) after the age of 75. We also established a "control cohort" comprising 297 subjects from the 3-city cohort, none of whom had experienced CVE before inclusion. This allowed us to assess the effects of CHIP and mLOY on inflammation and atherosclerosis independently of pre-existing cardiovascular disease. Our analysis revealed a remarkably high frequency of CHIP, with an estimated prevalence of 45% among our 446 subjects, with a median age of 76.4 years. This prevalence exceeded

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

initial reports of 15-20% determined by whole exome sequencing (WES) in individuals aged 70-80,^{2,23} likely attributable to the enhanced sensitivity of our sequencing technique. Importantly, our estimated prevalence aligns with studies employing similarly sensitive highthroughput sequencing techniques.²⁴⁻²⁷ Furthermore, our approach allowed us to reliably detect mutations with a variant allele frequency (VAF) as low as 1%. We chose to define subjects with detectable mutations at a VAF of 1% as CHIP(-), aligning with the WHO definition of CHIP.²⁸ Notably, all our analyses also yielded identical results when comparing CHIP(+) patients to subjects without detectable mutations. A recent study by Mas-Peiro et al. demonstrated an association between mLOY and increased post-transcatheter aortic valve replacement (TAVR) mortality.²⁹ In their investigation, a mLOY ratio threshold of 17% was deemed the most relevant for discriminating patients' mortality risk. In our study, we employed a mLOY threshold of 9% to identify mLOY, a value determined through DNA samples from patients for whom the absence of mLOY had been definitively established through conventional cytogenetic analysis and an age below 40 years. Using this threshold, we frequently detected mLOY in male subjects within our cohort, with an estimated prevalence of 37.7% among 220 subjects. This prevalence surpasses that reported by Forsberg et al ³⁰ but aligns with recent findings from studies employing sensitive techniques. 16 Surprisingly, our cohort did not reveal any significant association between the presence of CHIP and the detection of mLOY. This contrasts with the results of two recent studies. 15,16 possibly explained by the heightened sensitivity of our methodology in reliably detecting both somatic mutations and mLOY, which may exist in very small proportions of blood cells. Mouse models of CHIP have recently suggested that somatic mutations are linked to a proinflammatory phenotype of mutated monocytes/macrophages, an observation supported by human samples using single-cell RNA sequencing.³¹ However, contradictory results have emerged when examining plasmatic markers of inflammation. Studies, including ours, have

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

not consistently identified a significant increase in plasma hsCRP or proinflammatory cytokines in CHIP carriers, 25,32 whereas others have reported such associations. 20,21 Importantly, our study did not observe any significant association between the detection of CHIP(+/-)mLOY and plasma levels of IL1ß and IL6 in MI(+) subjects, suggesting that CHIP's association with increased systemic inflammation may depend on specific stimulating factors. Notably, recent studies have reported elevated levels of plasma inflammatory markers in CHIP carriers during atherothrombotic events, such as MI or stroke, 33-35 indicating that CHIP may amplify systemic inflammation under specific conditions, but not necessarily in a basal state, as in our study. To date, only a limited number of studies have successfully linked the presence of CHIP to an increased atherosclerotic burden. While Jaiswal et al. reported a higher calcic score in subjects with CHIP4, and Zekavat et al. suggested an increased atherosclerosis, 22 these evaluations relied on self-reported atheroma and indirect parameters. Our study stands as the first to utilize direct markers of atherosclerosis, including global atheroma volume, in CHIP(+) subjects within the context of coronary artery disease. Strikingly, we did not detect a clear increase in atherosclerosis among CHIP or mLOY carriers, either individually or in combination. Conversely, increased atherosclerotic burden associated with CHIP has been observed in patients with stroke.36 Our cohort comprising 449 subjects was unable to establish a direct association between CHIP, either alone or in conjunction with mLOY, and coronary heart disease. These results align with previous studies that reported either no difference in CHIP prevalence between individuals with MI and those without, 21 or no significant association between CHIP and incident de novo or recurrent atherothrombotic events. 7,34,37 Recently, Kessler et al. proposed that the increased risk of atherothrombotic events might be limited to CHIP with a VAF of 10% or higher.⁶ However, even when considering this criterion, the association was not validated in a cohort of 173,585 subjects. Notably, at the time of our study's initiation, the

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

literature suggested an increased MI risk associated with CHIP, with a hazard ratio of 1.9-2.0. Based on this data, a cohort of 112 cases would have been sufficient to demonstrate a more frequent detection of CHIP in MI(+) patients compared to MI(-) subjects with a power of 0.90. This underscores the formidable challenges of identifying associations with low effect sizes, necessitating cohorts comprising hundreds of thousands of subjects to achieve statistical significance. Regarding specific mutations in DNMT3A, TET2 or other genes, our study did not reveal differing effects on inflammation, atherosclerosis, or MI incidence. Collectively, these findings suggest that any atherothrombotic risk associated with CHIP is limited in scope. In conclusion, our study does not provide substantive evidence supporting a significant association between CHIP and substantial systemic inflammation, a pronounced increase in atherosclerotic burden, or a markedly elevated atherothrombotic risk. Additionally, mLOY did not appear to significantly modulate inflammation or atherosclerosis in the presence of CHIP. However, our data suggests that CHIP might expedite the onset of MI, particularly in the absence of mLOY. These findings warrant further investigation in larger subject cohorts. While our study bears some limitations, including a relatively modest sample size of 449 subjects and recruitment of subjects within 2 to 7 months post-MI, it possesses strengths. Notably, we employed highly sensitive techniques for the reliable detection of both CHIP and mLOY, surpassing the capabilities of large cohort studies relying on whole exome sequencing and SNP arrays. Furthermore, we meticulously assessed atherosclerotic burden using sensitive parameters and conducted a thorough evaluation of two cohorts—one comprising MI(+) subjects and the other MI(-) subjects—with precise cardiovascular phenotyping at inclusion and rigorous follow-up, including direct evaluation and adjudication of all CVE.

In summary, our findings provide a nuanced perspective on the relationship between CHIP, mLOY, and cardiovascular outcomes, highlighting the need for larger, more comprehensive studies to elucidate potential associations further.

Acknowledgements

The authors would like to thank the CRB-K of the University Hospital of Bordeaux for processing of the samples and Coralie Foucault and the Agilent Society for their partnership in supplying NGS reactive. We also thank Marina Migeon, Joël Decombe and Candice Falourd for their technical help, as well as Christel Duprat and Matthieu Meilhan for operational organization of the project.

Authorship

TC, OM and CJ designed the study. SF, YP, TC, AG and JB enrolled the subjects in the CHAth study and performed all cardiovascular evaluation. AS, CT and SD set up the 3 City Study Cohort. AB, SM, OM analyzed the NGS data. MD and DAT realized the statistical analysis. SF, SM, MD, DAT, CJ, OM and TC wrote the paper. All authors read and agreed to the final version of the manuscript.

References

- 463 1. Berry JD, Ning H, Horn LV, Lloyd-Jones DM. Lifetime Risks of Cardiovascular
- 464 Disease. N Engl J Med 2012:9.
- 465 2. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
- 466 Mermel CH, Burtt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B,
- 467 Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S,
- Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L,
- 469 Atzmon G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-Related Clonal Hematopoiesis
- 470 Associated with Adverse Outcomes. N Engl J Med 2014;371:2488–2498.
- 471 3. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert
- 472 BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic
- 473 syndromes. *Blood* 2015;**126**:9–16.
- 474 4. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M,
- 475 Gupta N, Gabriel S, Ardissino D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P,
- Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal
- 477 Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med
- 478 2017;**377**:111–121.
- 479 5. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R,
- Wu C-L, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AAB,
- 481 Cooper MA, Andrés V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated
- 482 with TET2 deficiency accelerates atherosclerosis development in mice. Science
- 483 2017;**355**:842–847.
- 484 6. Kessler MD, Damask A, O'Keeffe S, Van Meter M, Banerjee N, Semrau S, Li D,
- 485 Watanabe K, Horowitz J, Houvras Y, Gillies C, Mbatchou J, White RR, Kosmicki JA, LeBlanc
- 486 MG, Jones M, Regeneron Genetics Center, GHS-RGC DiscovEHR Collaboration, Glass DJ,
- 487 Lotta LA, Cantor MN, Atwal GS, Locke AE, Ferreira MAR, Deering R, Paulding C, Shuldiner
- 488 AR, Thurston G, Salerno W, Reid JG, Overton JD, Marchini J, Kang HM, Baras A, Abecasis
- 489 GR, Jorgenson E. Exome sequencing of 628,388 individuals identifies common and rare

- 490 variant associations with clonal hematopoiesis phenotypes
- 491 7. Kar SP, Quiros PM, Gu M, Jiang T, Langdon R, Iyer V, Barcena C, Vijayabaskar MS,
- 492 Fabre MA, Carter P, Burgess S, Vassiliou GS. Genome-wide analyses of 200,453 individuals
- 493 yields new insights into the causes and consequences of clonal hematopoiesis
- 494 8. Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, Libby P,
- 495 Kathiresan S, Natarajan P. Genetic Interleukin 6 Signaling Deficiency Attenuates
- 496 Cardiovascular Risk in Clonal Hematopoiesis. Circulation 2020;**141**:124–131.
- 497 9. Vlasschaert C, Heimlich JB, Rauh MJ, Natarajan P, Bick AG. Interleukin-6 Receptor
- 498 Polymorphism Attenuates Clonal Hematopoiesis-Mediated Coronary Artery Disease Risk
- 499 Among 451 180 Individuals in the UK Biobank, Circulation 2023;147:358–360.
- 500 10. Saiki R, Momozawa Y, Nannya Y, Nakagawa MM, Ochi Y, Yoshizato T, Terao C,
- 501 Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T,
- 502 Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S.
- 503 Combined landscape of single-nucleotide variants and copy number alterations in clonal
- 504 hematopoiesis. *Nat Med* 2021;**27**:1239–1249.
- 505 11. Wright DJ, Day FR, Kerrison ND, Zink F, Cardona A, Sulem P, Thompson DJ,
- 506 Sigurjonsdottir S, Gudbjartsson DF, Helgason A, Chapman JR, Jackson SP, Langenberg C,
- 507 Wareham NJ, Scott RA, Thorsteindottir U, Ong KK, Stefansson K, Perry JRB. Genetic
- 508 variants associated with mosaic Y chromosome loss highlight cell cycle genes and overlap
- with cancer susceptibility. Nat Genet 2017;49:674–679.
- 510 12. Zhou W, Machiela MJ, Freedman ND, Rothman N, Malats N, Dagnall C, Caporaso N,
- Teras LT, Gaudet MM, Gapstur SM, Stevens VL, Jacobs KB, Sampson J, Albanes D,
- Weinstein S, Virtamo J, Berndt S, Hoover RN, Black A, Silverman D, Figueroa J, Garcia-
- 513 Closas M, Real FX, Earl J, Marenne G, Rodriguez-Santiago B, Karagas M, Johnson A,
- 514 Schwenn M, Wu X, Gu J, Ye Y, Hutchinson A, Tucker M, Perez-Jurado LA, Dean M, Yeager
- 515 M, Chanock SJ. Mosaic loss of chromosome Y is associated with common variation near
- 516 TCL1A. Nat Genet 2016;48:563-568.
- 517 13. Loftfield E, Zhou W, Graubard BI, Yeager M, Chanock SJ, Freedman ND, Machiela

- 518 MJ. Predictors of mosaic chromosome Y loss and associations with mortality in the UK
- 519 Biobank. Sci Rep 2018;8:12316.
- 520 14. Sano S, Horitani K, Ogawa H, Halvardson J, Chavkin NW, Wang Y, Sano M,
- 521 Mattisson J, Hata A, Danielsson M, Miura-Yura E, Zaghlool A, Evans MA, Fall T, De Hoyos
- 522 HN, Sundström J, Yura Y, Kour A, Arai Y, Thel MC, Arai Y, Mychaleckyj JC, Hirschi KK,
- 523 Forsberg LA, Walsh K. Hematopoietic loss of Y chromosome leads to cardiac fibrosis and
- 524 heart failure mortality. *Science* 2022;**377**:292–297.
- 525 15. Ljungström V, Mattisson J, Halvardson J, Pandzic T, Davies H, Rychlicka-Buniowska
- 526 E, Danielsson M, Lacaze P, Cavelier L, Dumanski JP, Baliakas P, Forsberg LA. Loss of Y
- and clonal hematopoiesis in blood-two sides of the same coin? *Leukemia* 2022;**36**:889–891.
- 528 16. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I,
- 529 Thorgeirsson TE, Sigurdsson A, Gudjonsson SA, Gudmundsson J, Jonasson JG,
- Tryggvadottir L, Jonsson T, Helgason A, Gylfason A, Sulem P, Rafnar T, Thorsteinsdottir U,
- 531 Gudbjartsson DF, Masson G, Kong A, Stefansson K. Clonal hematopoiesis, with and without
- 532 candidate driver mutations, is common in the elderly. *Blood* 2017;**130**:742–752.
- 533 17. 3C Study Group. Vascular factors and risk of dementia: design of the Three-City
- 534 Study and baseline characteristics of the study population. Neuroepidemiology 2003;22:316–
- 535 325.
- 536 18. Lafitte M, Pucheu Y, Latry K, Dijos M, Casassus E, Couffinhal T. Predictors of
- 537 cardiovascular prognosis in patients receiving optimized secondary prevention measures
- after acute coronary syndrome. *Eur J Prev Cardiol* 2013;**20**:283–290.
- 539 19. Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto J-C, Dupriez B,
- Boyer F, Renard M, Mansier O, Murati A, Rey J, Etienne G, Mansat-De Mas V, Tavitian S,
- Nibourel O, Girault S, Le Bris Y, Girodon F, Ranta D, Chomel J-C, Cony-Makhoul P, Sujobert
- P, Robles M, Ben Abdelali R, Kosmider O, Cottin L, Roy L, Sloma I, Vacheret F, Wemeau M,
- 543 Mossuz P, Slama B, Cussac V, Denis G, Walter-Petrich A, Burroni B, Jézéquel N, Giraudier
- 544 S, Lippert E, Socié G, Kiladjian J-J, Ugo V. Genomic analysis of primary and secondary
- 545 myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv

- 546 2021;**5**:1442–1451.
- 547 20. Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Leventhal MJ, Bao EL, Nasser J,
- Zekavat SM, Szeto MD, Laurie C, Taub MA, Mitchell BD, Barnes KC, Moscati A, Fornage M,
- 549 Redline S, Psaty BM, Silverman EK, Weiss ST, Palmer ND, Vasan RS, Burchard EG, Kardia
- 550 SL, He J, Kaplan RC, Smith NL, Arnett DK, Schwartz DA, Correa A, Andrade M de, Guo X,
- Konkle BA, Custer B, Peralta JM, Gui H, Meyers DA, McGarvey ST, Chen IY-D, Shoemaker
- 552 MB, Peyser PA, Broome JG, Gogarten SM, Wang FF, Wong Q, Montasser ME, Daya M,
- Kenny EE, North K, Launer LJ, Cade BE, Bis JC, Cho MH, Lasky-Su J, Bowden DW,
- 554 Cupples LA, Mak AC, Becker LC, Smith JA, Kelly TN, Aslibekyan S, Heckbert SR, Tiwari HK,
- 555 Yang IV, Heit JA, Lubitz SA, Rich SS, Johnsen JM, Curran JE, Wenzel S, Weeks DE, Rao
- 556 DC, Darbar D, Moon J-Y, Tracy RP, Buth EJ, Rafaels N, Loos RJ, Hou L, Lee J, Kachroo P,
- 557 Freedman BI, Levy D, Bielak LF, Hixson JE, Floyd JS, Whitsel EA, Ellinor P, Irvin MR,
- 558 Fingerlin TE, Raffield LM, Armasu SM, Rotter JI, Wheeler MM, Sabino EC, Blangero J,
- Williams LK, Levy BD, Sheu WH-H, Roden DM, Boerwinkle E, Manson JE, Mathias RA,
- 560 Desai P, Taylor KD, Johnson A, Auer PL, Kooperberg C, Laurie CC, Blackwell TW, Smith
- 561 AV, Zhao H, Lange E, Lange L, Wilson JG, Lander ES, Engreitz JM, Ebert BL, Reiner AP,
- Sankaran VG, Jaiswal S, Abecasis G, Natarajan P, Kathiresan S, on behalf of the NHLBI
- 563 Trans-Omics for Precision Medicine (TOPMed) Consortium. Inherited Causes of Clonal
- 564 Hematopoiesis of Indeterminate Potential in TOPMed Whole Genomes
- 565 21. Busque L, Sun M, Buscarlet M, Ayachi S, Feroz Zada Y, Provost S, Bourgoin V,
- Mollica L, Meisel M, Hinterleitner R, Jabri B, Dubé M-P, Tardif J-C. High-sensitivity C-
- 567 reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Adv
- 568 2020;**4**:2430–2438.
- 569 22. Zekavat SM, Viana-Huete V, Matesanz N, Jorshery SD, Zuriaga MA, Uddin MM,
- 570 Trinder M, Paruchuri K, Zorita V, Ferrer-Pérez A, Amorós-Pérez M, Kunderfranco P, Carriero
- 571 R, Greco CM, Aroca-Crevillen A, Hidalgo A, Damrauer SM, Ballantyne CM, Niroula A,
- 572 Gibson CJ, Pirruccello J, Griffin G, Ebert BL, Libby P, Fuster V, Zhao H, Ghassemi M,
- 573 Natarajan P, Bick AG, Fuster JJ, Klarin D. TP53-mediated clonal hematopoiesis confers

- 574 increased risk for incident atherosclerotic disease. Nat Cardiovasc Res 2023:1–15.
- 575 23. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF,
- 576 Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund
- 577 M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H,
- 578 Hultman CM, McCarroll SA. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from
- 579 Blood DNA Sequence. *N Engl J Med* 2014;**371**:2477–2487.
- 580 24. Guermouche H, Ravalet N, Gallay N, Deswarte C, Foucault A, Beaud J, Rault E,
- Saindoy E, Lachot S, Martignoles J-A, Gissot V, Suner L, Gyan E, Delhommeau F, Herault
- 582 O, Hirsch P. High prevalence of clonal hematopoiesis in the blood and bone marrow of
- 583 healthy volunteers. *Blood Adv* 2020;**4**:3550–3557.
- 584 25. Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, Hernández-Vicente Á, Vázquez-
- Andrés D, Barrera J de la, Vazquez E, Quintas A, Zuriaga MA, Asensio-López MC, Dopazo
- 586 A, Sánchez-Cabo F, Fuster JJ. Clonal Hematopoiesis and Risk of Progression of
- 587 Heart Failure With Reduced Left Ventricular Ejection Fraction. J Am Coll Cardiol
- 588 2021;**77**:1747–1759.
- 589 26. Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA, Dimmeler S,
- 590 Vasa-Nicotera M, Zeiher AM. Clonal haematopoiesis in patients with degenerative aortic
- 591 valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J 2020;41:933–
- 592 939.
- 593 27. Zeventer IA van, Salzbrunn JB, Graaf AO de, Reijden BA van der, Boezen HM, Vonk
- 594 JM, Harst P van der, Schuringa JJ, Jansen JH, Huls G. Prevalence, predictors, and
- 595 outcomes of clonal hematopoiesis in individuals aged ≥80 years. Blood Adv 2021;5:2115-
- 596 2122.
- 597 28. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E,
- 598 Busque L, Chan JKC, Chen W, Chen X, Chng W-J, Choi JK, Colmenero I, Coupland SE,
- 599 Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile J-F, Ferry J, Fogelstrand L,
- 600 Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH,
- 601 Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li X-Q, Lim MS, Loeb K, Loghavi S,

- 602 Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron
- 603 E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R,
- Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. The
- 5th edition of the World Health Organization Classification of Haematolymphoid Tumours:
- Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36:1703–1719.
- 607 29. Mas-Peiro S, Abplanalp WT, Rasper T, Berkowitsch A, Leistner DM, Dimmeler S,
- Zeiher AM. Mosaic loss of Y chromosome in monocytes is associated with lower survival
- after transcatheter aortic valve replacement. Eur Heart J 2023;44:1943–1952.
- 610 30. Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, Sandgren
- J, Diaz de Ståhl T, Zaghlool A, Giedraitis V, Lannfelt L, Score J, Cross NCP, Absher D,
- 612 Janson ET, Lindgren CM, Morris AP, Ingelsson E, Lind L, Dumanski JP. Mosaic loss of
- 613 chromosome Y in peripheral blood is associated with shorter survival and higher risk of
- 614 cancer. Nat Genet 2014;46:624-628.
- 615 31. Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, Rieger
- 616 MA, Vasa-Nicotera M, Zeiher AM, Dimmeler S. Clonal Hematopoiesis-Driver DNMT3A
- 617 Mutations Alter Immune Cells in Heart Failure. Circ Res 2021;128:216–228.
- 618 32. Cook EK, Izukawa T, Young S, Rosen G, Jamali M, Zhang L, Johnson D, Bain E,
- 619 Hilland J, Ferrone CK, Buckstein J, Francis J, Momtaz B, McNaughton AJM, Liu X,
- 620 Snetsinger B, Buckstein R, Rauh MJ. Comorbid and inflammatory characteristics of genetic
- subtypes of clonal hematopoiesis. *Blood Adv* 2019;**3**:2482–2486.
- 622 33. Wang S, Hu S, Luo X, Bao X, Li J, Liu M, Lv Y, Zhao C, Zeng M, Chen X, Unsworth
- 623 A, Jones S, Johnson TW, White SJ, Jia H, Yu B. Prevalence and prognostic significance of
- 624 DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-
- segment elevation myocardial infarction. *eBioMedicine* 2022;**78**:103964.
- 626 34. Arends CM, Liman TG, Strzelecka PM, Kufner A, Löwe P, Huo S, Stein CM, Piper
- 627 SK, Tilgner M, Sperber PS, Dimitriou S, Heuschmann P, Hablesreiter R, Harms C, Bullinger
- 628 L, Weber JE, Endres M, Damm F. Associations of clonal haematopoiesis with recurrent
- 629 vascular events and death in patients with incident ischemic stroke. Blood

- 630 2022:blood.2022017661.
- 631 35. Böhme M, Desch S, Rosolowski M, Scholz M, Krohn K, Büttner P, Cross M,
- Kirchberg J, Rommel K-P, Pöss J, Freund A, Baber R, Isermann B, Ceglarek U, Metzeler
- KH, Platzbecker U, Thiele H. Impact of Clonal Hematopoiesis in Patients With Cardiogenic
- 634 Shock Complicating Acute Myocardial Infarction. *J Am Coll Cardiol* 2022;**80**:1545–1556.
- 635 36. Mayerhofer E, Strecker C, Becker H, Georgakis MK, Uddin MM, Hoffmann MM,
- Nadarajah N, Meggendorfer M, Haferlach T, Rosand J, Natarajan P, Anderson CD, Harloff A,
- 637 Hoermann G. Prevalence and Therapeutic Implications of Clonal Hematopoiesis of
- 638 Indeterminate Potential in Young Patients With Stroke. Stroke 2023.
- 639 37. David C, Duployez N, Eloy P, Belhadi D, Chezel J, Guern VL, Laouénan C, Fenwarth
- 640 L, Rouzaud D, Mathian A, Almeida Chaves S de, Duhaut P, Fain O, Galicier L, Ghillani-
- Dalbin P, Kahn JE, Morel N, Perard L, Pha M, Sarrot-Reynauld F, Aumaitre O, Chasset F,
- 642 Limal N, Desmurs-Clavel H, Ackermann F, Amoura Z, Papo T, Preudhomme C, Costedoat-
- 643 Chalumeau N, Sacre K. Clonal haematopoiesis of indeterminate potential and cardiovascular
- 644 events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatol Oxf Engl
- 645 2022;**61**:4355–4363.

Figure 1: CHIP, mLOY and their combination are as frequent in MI(+) and MI(-) subjects

A: Prevalence of CHIP, mLOY and their combination in the total cohort of 449 subjects, in MI(+) as well as in MI(-) subjects. B: Mutational spectrum of CHIP expressed as the proportion of mutations detected in the indicated genes. C: VAF measured for the different mutations detected in the 449 subjects detected in the indicated genes. D: Prevalence of CHIP and mLOY depending on age in the total cohort (for CHIP) and in male subjects (for mLOY).

Figure 2: CHIP and mLOY do not increase significantly the risk of incident MI, but could accelerate it in male subjects.

Incidence of MI during follow up according to the presence of CHIP (A) or mLOY (B) in MI(-) subjects. Incidence of MI during follow up according to the presence of CHIP (C) or the combination of CHIP and mLOY (D) in male MI(-) subjects. Survival was compared between the different groups with log-rank tests.





Figure 1



medRxiv preprint doi: https://doi.org/10.1101/2024.01.15.24301313; this version posted January 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Table 1: Characteristics of the population at the time of inclusion

| rabio ii characteriotice er tile pepala | | | | |
|---|------------------|------------------|------------------|----------------------|
| | All subjects | MI(+) subjects | MI(-) subjects | |
| | n = 446 | n=149 | n=297 | p-value |
| | | | | |
| Male, n (%) | 257 (57.6) | 98 (66) | 159 (54) | 0.015 |
| Median age, years (Q1;Q3) | 76.4 (71.9;80.9) | 82.0 (78.0;86.0) | 73.6 (70.6;77.8) | P < 10 ⁻⁴ |
| Cardiovascular risk factors | | | | |
| BMI, kg/m ² (Q1;Q3) | 25.5 (23.6;28.3) | 25.5 (23.6;28.5) | 25.5 (23.6;28.1) | 0.14 |
| Diabetes, n (%) | 94 (21.2) | 47 (32%) | 47 (16%) | p < 10 ⁻⁴ |
| Hypertension, n (%) | 362 (82.8) | 107 (76.4) | 255 (85.9) | 0.020 |
| Total cholesterol, g/L (Q1;Q3) | 2.08 (1.72;2.38) | 1.45 (1.25;1.72) | 2.23 (2.00;2.47) | p < 10 ⁻⁴ |
| LDL-c, g/L (Q1;Q3) | 1.25 (0.94;1.52) | 0.77 (0.61;1.03) | 1.39 (1.19;1.60) | p < 10 ⁻⁴ |
| HDL-c, g/L (Q1;Q3) | 0.56 (0.46;0.66) | 0.47 (0.39;0.57) | 0.59 (0.50;0.68) | p < 10 ⁻⁴ |
| Smoking, n (%) | 32 (7.2) | 6 (4.4) | 26 (8.7) | 0.117 |
| Prevalence of CHIP and mLOY | | | | |
| CHIP prevalence, n (%) | 201 (45.1) | 79 (53%) | 122 (41%) | 0.923 |
| Prevalence of CHIP with VAF ≥5% | 88 (19.7) | 30 (20.1) | 58 (19.5) | 0.069 |
| Subjects tested for mLOY, n | 220 | 97 | 123 | - |
| mLOY prevalence, n (%) | 83 (37.7) | 44 (45.4) | 39 (31.7) | 0.783 |
| CHIP(+) / mLOY(+) prevalence, n (%) | 39 (17.7) | 22 (22.7) | 17 (13.8) | 0.797 |

Data are expressed as numbers and frequency or median, first and third quartiles. For quantitative values, comparisons were made by linear regression of log values adjusted for age and sex. For qualitative parameters, comparisons were made by the fisher test. For each variable, results are expressed among patients with available value.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.15.24301313; this version posted January 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Table 2: CHIP and mLOY are not associated with increased hsCRP level

| | hsCRP level | р | hsCRP level | р | hsCRP level | р |
|-------------------|------------------|-------|------------------|-------|------------------|-------|
| | All subjects | value | MI(+) subjects | value | MI(-) subjects | value |
| CHIP(-) | 1.64 (1.00;3.69) | 0.652 | 1.40 (1.00;4.00) | 0.600 | 1.71 (0.97;3.22) | 0.141 |
| CHIP(+) | 2.00 (1.00:3.90) | | 2.20 (1.10;5.00) | | 1.63 (0.91;2.54) | |
| mLOY(-) | 1.45 (0.99;2.75) | 0.156 | 1.8 (1.0;4.8) | 0.149 | 1.41 (0.74;2.16) | 0.358 |
| mLOY(+) | 1.73 (1.01;4.00) | | 2.4 (1.03;4.5) | | 1.2 (0.99;2.99) | |
| CHIP (-) mLOY (-) | 1.11 (0.76;2.19) | 0.410 | 1.00 (0.77;2.72) | 0.430 | 1.35 (0.79;2.14) | 0.570 |
| CHIP (+) mLOY (-) | 1.87 (1.00;3.03) | | 2.30 (1.35;7.35) | | 1.43 (0.72;2.37) | |
| CHIP (-) mLOY (+) | 2.20 (1.02;4.00) | | 2.50 (1.30;4.00) | | 1.37 (0.95;3.75) | |
| CHIP (+) mLOY (+) | 1.23 (1.01;3.80) | | 2.00 (1.02;4.75) | | 1.17 (1.03;1.73) | |

hsCRP Data are expressed as median, first and third quartiles. Comparisons were performed by linear regression of log values adjusted for age and sex. hsCRP levels are expressed in mg/L For each variable, results are expressed among patients with available value.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.15.24301313; this version posted January 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Table 3: CHIP and mLOY are not associated with an increased atherosclerotic burden

| Atherosclerosis burden evaluation in MI(+) subjects | | | | | | | | |
|---|---------------------------|---------------------------|---------------------------|---------|-----------------------------|--------------------------|---------|--|
| | All patients | CHIP (-) | CHIP (+) | p- | mLOY (-) | mLOY (+) | p-value | |
| | (n = 149) | (n = 70) | (n = 79) | value | (n = 53) | (n = 44) | p-value | |
| Multitroncular lesions, n (%) | 68 (45.6) | 29 (41.4) | 39 (49.4) | 0.484 | 25 (47.2) | 20 (45.4) | 0.717 | |
| Carotid stenosis ≥ 50%, n (%) | 7 (4.7) | 2 (2.8) | 5 (6.3) | 0.317 | 2 (3.8) | 3 (6.8) | 0.451 | |
| Global atheroma volume | 499.5 | 455.0 | 520.0 | 0 222 | 601.0 | 492.0 | 0.707 | |
| (mm ³), median (Q1;Q3) | (408.0;604.5) | (374.0;555.0) | (411.5;611.5) | 0.333 | (412.0;718.0) | (344.5;600.5) | 0.707 | |
| Atherosclerosis burden evaluation in MI(-) subjects | | | | | | | | |
| | All patients (n = 297) | CHIP (-) (n = 175) | CHIP (+) (n = 122) | p-value | mLOY (-) (n = 84) | mLOY (+) (n = 39) | p-value | |
| Patients with atherosclerotic plaque, n (%) | 135 (45.4) | 81 (46.3) | 54 (44.3) | 0.997 | 34 (40.5) | 19 (48.7) | 0.537 | |
| Number of plaque, median (Q1;Q3) | 1 (1;2) | 2 (1;2) | 1 (1;2) | 0.258 | 2 (1;2) | 2 (1;2) | 0.863 | |
| Intima Media Thickness (mm), median (Q1;Q3) | 0.68 (0.60;0.76) | 0.67 (0.60;0.76) | 0.68 (0.59;0.74) | 0.897 | 0.67 (0.62;0.76) | 0.72 (0.57;0.83) | 0.706 | |

Data are expressed as numbers and frequency or median, first and third quartiles. For quantitative values, comparisons were made by linear regression of log values adjusted for age and sex. For qualitative parameters, comparisons were made by the fisher test and logistic regression. For each variable, results are expressed among patients with available value.